搏动性儿童心室辅助装置支持后心脏移植的长期结局
本研究基于PHTS与Berlin Heart IDE数据库链接数据,回顾性比较2007-2011年接受心脏移植的儿童中,VAD支持者与无需MCS的匹配对照者的长期结局。结果显示VAD组与对照组5年生存率无统计学差异(81% vs 88%;p=0.09),排斥反应及感染发生率亦无差异。提示Berlin Heart VAD作为儿童移植前过渡支持具有与无MCS支持者相似的移植后结局。
要点
- 儿童VAD支持后移植者5年生存率与无MCS支持者无统计学差异(81% vs 88%;p=0.09)。
- VAD组与对照组在排斥反应及感染发生率上均无差异。
- Berlin Heart IDE试验人群移植后仍需持续监测。
核心结论
- 儿童使用Berlin Heart VAD支持后心脏移植的生存率、感染及排斥反应发生率与无需MCS支持者相似。
研究设计与样本
- 回顾性研究,链接PHTS与Berlin Heart IDE数据库,纳入2007-2011年≤18岁心脏移植受者,随访不足5年者排除,VAD支持者按1:2匹配非VAD对照。
- 109例Berlin Heart IDE入组者中83例与PHTS数据库合并,匹配166例非MCS支持患者。
主要发现
- VAD组与匹配对照组5年患者生存率无统计学差异(81% vs 88%;p=0.09)。
- VAD组与对照组在无排斥反应生存及无感染生存方面均无差异。
- 两组在诊断、登记时状态及年龄方面无差异,非MCS支持组正性肌力药使用存在预期差异。
临床怎么用
- 对于拟行心脏移植的儿童,Berlin Heart VAD作为桥接支持不增加移植后5年死亡、排斥或感染风险。
- Berlin Heart IDE试验人群移植后仍需持续随访监测长期结局。
局限性
- 为回顾性研究,仅纳入随访≥5年的患者。
- 样本量有限,VAD组83例、对照组166例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There has been increasing use of durable ventricular assist devices (VAD) in children as a bridge to transplantation (BTT). The Berlin Heart investigational device exemption (IDE) trial was the first pediatric VAD trial to demonstrate excellent survival outcomes as a BTT. OBJECTIVES: Our aim was to compare the expanded post-transplant outcomes for children enrolled in the Berlin Heart IDE trial to a matched Pediatric Heart Transplant Study (PHTS) cohort not requiring mechanical circulatory support (MCS). SETTING: University Hospitals. METHODS: This was a retrospective review of linked PHTS and Berlin Heart IDE databases for pediatric (≤18 years) recipients transplanted from 2007-2011. Subjects with <5 years of follow up were excluded. VAD supported patients were matched 1:2 to non-VAD supported controls from the PHTS database. RESULTS: Among 109 Berlin Heart IDE study enrollees, 83 were merged with the PHTS database and matched to 166 non-MCS supported patients. There was no difference in diagnosis, status at listing, and age between groups with the expected difference in inotrope use in the non-MCS supported patients. Compared to their matched cohort, there was no statistical difference in 5-year patient survival between VAD and non-VAD patients (81% vs 88%; p = 0.09) nor was there a difference in freedom from rejection or infection. CONCLUSIONS: This data suggests that children supported with a Berlin Heart VAD had similar survival, infection and rejection rates compared to those not requiring MCS support. Continued surveillance of the Berlin Heart IDE trial population post heart transplantation is warranted.
引用
- Jeewa A, Imamura M, Canter C, et al. Long-term outcomes after transplantation after support with a pulsatile pediatric ventricular assist device. J Heart Lung Transplant. 2018. PMID: 30466802. doi:10.1016/j.healun.2018.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。